Ashwin Kishtagari, MD
@AshKishtagari
Assistant Professor @VUMC_Cancer in Leukemia/MDS/MPN/CH. Alumni of @ClevelandClinic @msm_msw @kmc_manipal Tweets are my own.
I am honored to be a co-first author of our latest publication in @CD_AACR! This collaboration between @VUMC_Cancer and @UTSWMedCenter reveals how non-selective β-blockers impair hematopoietic regeneration after HCT. Our findings highlight the critical role of β-adrenergic…
The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by @AshKishtagari of @VUMCDiscoveries. shorturl.at/RkY2M #EHA2025 #leusm #mdssm
Opinion: Top Studies From EHA 2025 @CancerTherAdvsr cancertherapyadvisor.com/features/top-s…
Honored & humbled to receive #BeutlerPrize along w/#RadekSkoda. Measuring #MPN Symptoms & developing the 4 JAKi = #TEAM of dedicated MPN Patients/Investigators/#PharmaColleagues @harrisoncn1 #SergeVerstovsek @jjkiladjian #Vannuchi @RobynScherber #JoyceNiblack @wakeforestmed
ASH is proud to recognize 11 hematologists whose groundbreaking research and leadership have transformed the understanding and care of blood disorders. Congratulations to all! 👏 🔗 ow.ly/EsgX50WbEwx #Hematology #ASHAwards
Congratulations @AshKishtagari and helping the next generations @VUMCDiscoveries @VUMChealth @jordanberlin5
I am thrilled to share our new publication in @eClinicalMedicine co-led with a superb @VUMChealth IM resident James Brogan: "Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis" sciencedirect.com/science/articl… We analyzed 805,249 participants…
As @FDAOncology’s ODAC weighed in today on the future of belantamab-based triplets, revisit this timely episode of @BloodCancerTalk with @HangQuach1, where we break down DREAMM-7 & DREAMM-8 and explore belantamab’s evolving role in myeloma treatment. 🎧 @Eddie_Cliff…
Our new episode-"Belantamab makes a comeback" with @HangQuach1 just dropped! We critically appraised DREAMM-7 and DREAMM-8 trials, and there are lots of clinical pearls on how to mitigate ocular toxicity! tinyurl.com/sen8cjnc Here is a clip on eye tox with belantamab:
Delighted to collaborate on this study led by @jieliu09 @KellyLBolton describing how germline genetic variation influences the trajectory of clonal hematopoiesis to hematologic malignancy nature.com/articles/s4158… @NatureGenet
Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. nature.com/articles/s4137…
We are excited to share our work on "closing the loop" 🔄 - a framework enabling single-cell foundation models (scFMs) to learn from experimental validation and dramatically improve their predictive accuracy! (1/n)
A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm @rajshekharucms @Eddie_Cliff @MeeraMohanMD podcasts.apple.com/us/podcast/blo…
Happy to share our newest work out today in BCD evaluating disease classification and prognosis in the “world of myeloid malignancies”! Wonderful collaboration with @sanamloghavi @PapaemmanuilLab @Elsa2Bernard and colleagues.
Online First: Multi-Modal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification Across Disease States brnw.ch/21wTSQI
Great use of scDNAseq and other MRD techniques to show the power of precision oncology. Love it! Congratulations!! @TaylorJ_MD @JustinWattsMD @FerrellLabVUMC @AshKishtagari
Our new paper is out @Nature_NPJ Precision Oncology! rdcu.be/eujnK With @JustinWattsMD and colleagues @SylvesterCancer we report on the first patient functionally cured by single-agent IDH1 inhibition with Olutasidenib @RigelPharma for r/r #AML @NaturePortfolio 🧵
Excited to see our NHLBI work on infections and immunodeficiency in patients with #telomere biology disorders now published in @BloodPortfolio. >1/3 had significant infection history and nearly 1/2 t-lymphopenia. @FernandoCatto & @fergutierrezro1. ashpublications.org/blood/article-…
Our new episode on overview of Menin Inhibitors in AML with @Doctor_E_Stein from @MSKCancerCenter just dropped! We had a great discussion on the landscape of menin inhibitors, along with some clinical pearls from Dr. Stein on management! share.transistor.fm/s/f91d6c00 @AshKishtagari
Low blood cell counts drive cancer in explosive blood disorder: study news.vumc.org/2025/06/23/low…
Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…
How reliable is plasma cell-free DNA for detection of clonal hematopoiesis? Would love to chat about it tonight at the #EHA25 poster session! Poster PS-2315 :)
Remarkable work by @yash_pershad and team on CHIP dynamics over 16 years in ~7,000 women out now in @BloodPortfolio! Longitudinal CHIP studies remain rare - this depth of follow-up is invaluable. Correlates and Consequences of Clonal Hematopoiesis Expansion Rate: A 16-Year…
🚨🚨Paper out! 🚨🚨 Delighted to share our work, now published in @NatureGenet 🧬! shorturl.at/94s5S We identified a targetable, chromothripsis-associated genetic event in blast phase (BP) MPN, a particularly poor prognostic subtype of acute leukaemia. 1/n 🧵👇
Fantastic study & findings from @AshKishtagari & VUMC collaborators like @AlexBickMDPhD ! Hopefully the start of many more studies to come.
I am thrilled to share our new publication in @eClinicalMedicine co-led with a superb @VUMChealth IM resident James Brogan: "Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis" sciencedirect.com/science/articl… We analyzed 805,249 participants…